Corcept Therapeutics Inc

Corcept Therapeutics is a commercial-stage biopharmaceutical company that discovers and develops medications that modulate the effects of the hormone cortisol to treat severe endocrinologic, oncologic, metabolic and neurologic disorders. Over more than 25 years it has discovered more than 1,000 proprietary selective glucocorticoid receptor (GR) antagonists. The company has two marketed franchises. The first is Korlym (mifepristone), introduced in 2012 as the first FDA-approved medication for endogenous Cushing's syndrome, sold together with an authorized generic. The second is Lifyorli (relacorilant), introduced in 2026 as the first FDA-approved selective GR antagonist, used with nab-paclitaxel for platinum-resistant ovarian cancer. Relacorilant is also under FDA review for Cushing's syndrome (PDUFA date December 17, 2026) and has a positive CHMP opinion in Europe for ovarian cancer. The pipeline includes relacorilant in endometrial, pancreatic, cervical and prostate cancers; nenocorilant with immunotherapy in solid tumors; miricorilant in MASH; and dazucorilant in ALS, with a Phase 3 trial planned. Updated Nov 3, 2026